Cancer Research Technology (CRT) has announced the establishment of a US subsidiary based in Boston and the recruitment of Larry Steranka as managing director
CRT Inc will provide oncology-focused technology transfer and development expertise to leading US not-for-profit research institutions and represent CRT in licensing discussions with US biopharmaceutical companies.
Through partnership with CRT, academic collaborators are able to bridge the fundamental development gap between exploratory research and industrial development of diagnostics and therapeutics in oncology.
Development of academic-based cutting edge discoveries will be carried out in conjunction with biotherapeutic and drug discovery groups within CRT's Development Laboratories.
Keith Blundy, CRT's COO and CRT Inc's chairman, stated "Through CRT Inc, Dr Steranka will reinforce our strategy of oncology-focused development of diagnostics and therapeutics in partnership with leading US academic institutions".
"Dr Steranka's experience, both in industry and academic-based technology transfer, will benefit CRT's operations on both sides of the Atlantic".
Prior to joining CRT as managing director, Larry Steranka was the executive director of Brandeis University's Office of Technology Licensing, and immediately before that, an associate director for Licensing at Harvard University's Office of Technology and Trademark Licensing.
Dr Steranka has also held senior positions within major pharmaceutical and biotechnology companies.
